PROM1 and neoplasm: Dendritic cells transfected with ANXA3 are capable of inducing more functionally active T cells able to recognise and eradicate CD133+ LCSCs.89 Last year, a Phase I clinical trial was reported to assess the toxicity and treatment efficacy of CD133-targeted chimeric antigen receptor (CAR-T) cells in a patient cohort consisting of HCC, pancreatic and colorectal patients.127 It was demonstrated that CD133-targeted CAR-T cells showed good specificity in eliminating CD133+ tumours.